Clinical trial management services firm Bioclinica has acquired Saliency, the developer of an artificial intelligence (AI)-based software that speeds medical image interpretation to help support pharmaceutical and medical device clients in clinical trials.
Saliency's platform uses proprietary algorithms to build and train AI models quickly from a small number of deidentified images. The models can be used to screen, redact, or interpret medical images to support numerous therapeutic areas.
The AI capability will be embedded into Bioclinica's current and future imaging products and services for research sponsors and clinical research organizations.
